Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases

Nathan A. Berger(University School), Csaba Szabó(Cincinnati Children's Hospital Medical Center), Ted M. Dawson(Johns Hopkins University), Alexander Bürkle(University of Konstanz), Raymond A. Swanson(San Francisco VA Medical Center), Balázs Sümegi(University of Pecs), Flavio Moroni(University of Florence), Valina L. Dawson(Johns Hopkins University), Alberto Chiarugi(University of Florence), György Haskó(Columbia University), Robert S. B. Clark(Royal United Hospital Bath NHS Trust), Lucas Liaudet(University of Lausanne), Valérie C. Besson(Inserm), Salvatore Cuzzocrea(University of Messina), Francisco García Soriano(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), A. Hamid Boulares(Stanley Foundation), Robert P. Strosznajder(Mossakowski Medical Research Institute, Polish Academy of Sciences), Pál Pacher(National Cancer Institute), Peter Radermacher(University Hospital Ulm), Nicola J. Curtin(Newcastle University), Andrew L. Salzman(Cincinnati Children's Hospital Medical Center), Solomon H. Snyder(Johns Hopkins University)
British Journal of Pharmacology
February 18, 2017
Cited by 210


Related Papers